Table 1. Study participants.
Participants are described individually for HIV+ group (top) and by group (bottom). Colors match with those in Figs. 1 (C, E, and F), 2 (B and C), 3A, 4 (A to C and E), and 6 (B and C) and fig. S1B and S2 (A and E). Excision sites were inguinal, except cervical for HIV13 and axillary for HIV2, HIV6, HIV10 and two of the HIV− group. Numbers in the last two rows are medians (range) or geometric mean (HIV RNA); bold indicates significant difference between the two groups. N/A, not applicable or not available. HIV neutralize, reported as geometric mean of titer.
| Participants HIV+ group |
Age (years) |
Gender (M/F) |
CD4+ T cell % |
CD4+ T cell (count/μl) |
CD8+ T cell (count/μl) |
CD19+ B cell (count/μl) |
HIV RNA (copies/ml) |
Years infected |
HIV neutralize |
|---|---|---|---|---|---|---|---|---|---|
| HIV1 | 23 | M | 25 | 532 | 1193 | 149 | 5924 | 1–5 | 22 |
| HIV2 | 26 | F | 19 | 304 | 1120 | 80 | 1804 | 1–5 | <20 |
| HIV3 | 26 | M | 23 | 336 | 746 | 161 | 847,180 | <1 | <20 |
| HIV4 | 29 | M | 16 | 253 | 823 | 142 | 33,691 | 1–5 | <20 |
| HIV5 | 25 | M | 45 | 714 | 524 | 175 | 1486 | <1 | <20 |
| HIV6 | 21 | M | 28 | 758 | 1055 | 568 | 35,576 | 1–5 | N/A |
| HIV7 | 53 | M | 43 | 404 | 376 | 94 | 20,594 | >20 | 79 |
| HIV8 | 34 | M | 27 | 583 | 1123 | 194 | 148 | 10–20 | 29 |
| HIV9 | 36 | F | 36 | 1206 | 823 | 268 | 94 | 1–5 | 25 |
| HIV10 | 44 | M | 20 | 494 | 1407 | 444 | 159 | >20 | 28 |
| HIV11 | 47 | M | 40 | 579 | 449 | 290 | 7199 | <1 | <20 |
| HIV12 | 39 | F | 27 | 551 | 1061 | 306 | 267 | 10–20 | 72 |
| HIV13 | 26 | M | 35 | 995 | 967 | 398 | 272 | 1–5 | N/A |
| HIV | 29 (21–53) |
10/3 |
27 (16–45) |
551 (253–1206) |
967 (376–1407) |
194 (80—568) |
2689 | ||
| HIV− | 40 (19–57) |
12/6 |
48 (37–66) |
632 (322–1401) |
286 (180–593) |
171 (95 – 275) |
N/A |